- Home
- SOWG vs PHIO Comparison
SOWG vs PHIO Comparison
Compare SOWG & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | PHIO |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 12.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOWG | PHIO |
|---|---|---|
| Price | $0.55 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | ★ 1.2M | 278.1K |
| Earning Date | 03-20-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,270,357.00 | N/A |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.81 |
| 52 Week High | $3.08 | $4.19 |
Technical Indicators
Market Signals| Indicator | SOWG | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 25.30 |
| Support Level | $0.63 | $1.09 |
| Resistance Level | $0.78 | $1.10 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 3.06 | 10.90 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.